ClinicalTrials.gg
CompletedNCT02015234BESTFIT-OLEUpdated Jul 7, 2017Results posted

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients

A Phase 3 interventional study of TNX-102 SL in Primary Fibromyalgia, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-07-07.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
158
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
100th of 320
158 · median 72
Started
2013
with 12 others
Phase 3
55 of 369
2 open now
Registered
188th of 369
by date
Lead sponsor
8 of 369
Tonix Pharmaceuticals, Inc.

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 100th largest by enrollment of the 320 interventional ones that give a count, is one of 13 that started in 2013, is one of 55 in phase 3, and was the 188th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

This was an open-label, extension trial designed to evaluate the long-term safety over 12 months of TNX-102 SL tablets taken daily at bedtime for the treatment of fibromyalgia. Patients recruited into this trial were those who had successfully completed the double-blind study, TNX-CY-F202 (F202) (NCT01903265). Patients were not made aware of the therapy they received during the double-blind study.

Read the detailed description

The study consisted of 7 clinic visits, including Screening/Baseline Visit 1 (Day 0 which was typically the same date as Visit 6 of the double-blind lead-in study), visits after 1, 3, 6, 9, and 12 months of treatment (Visits 2-6), and a Follow-up Visit (Visit 7) scheduled within one month after stopping study drug treatment.

Primary:

The primary objective of the study was to evaluate the long-term safety of TNX-102 SL tablets taken daily at bedtime over 12 months in patients with fibromyalgia who have completed Study TNX-CY-F202 (NCT01903265)

Secondary:

The secondary objective was to evaluate the long-term efficacy of TNX-102 SL tablets taken daily at bedtime to control symptoms of fibromyalgia

03

Conditions studied

  • Primary Fibromyalgia

Browse trials for

Keywords

  • TNX-102 SL
  • bedtime
  • sublingual
  • 12-month
  • long term safety
  • long term efficacy
  • Fibromyalgia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient met all prior inclusion and exclusion requirements for Study F202 (NCT01903265) originally, and has had no intervening medical conditions, increased suicidal ideation, or requirements for concomitant medications that preclude exposure to TNX-102 SL or enrollment in the extension study.
  2. The patient completed expected dosing in F202 (NCT01903265) defined as taking study medication up to Week 12, with at least 70% compliance with medication usage (based on responses from daily IVRS calls recorded during the F202 study (NCT01903265)) and no major protocol violations.
  3. The patient has provided written to participate in this extension protocol.

Exclusion criteria

Exclusion Criteria:

None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    TNX-102 SL

    1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months

    Drug: TNX-102 SL

Interventions

  • TNX-102 SL 2.8 mg taken daily at bedtime.

    Also known as: cyclobenzaprine HCl

06

What researchers measure

Primary outcomes

  1. Newly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL Tablets Taken Daily at Bedtime Over 12 Months in Patients With Fibromyalgia.

    NEAEs and Serious Adverse events (SAEs) were collected and are coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: Up to 12 months

Secondary outcomes

  1. Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on 24 Hour Recall

    The NRS for average pain was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 24-hour recall basis.

    Time frame: Months 1, 3, 6, 9 and 12.

  2. Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on a 7 Day Recall

    The NRS for average pain over the past 7 days was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 7-day recall basis.

    Time frame: Month 1, 3, 6, 9, 12

  3. Responder Analysis of Patient's Global Impression of Change (PGIC)

    PGIC is a fibromyalgia-specific validated instrument to gauge the patient's assessment of change in condition.The scores are categorized as provided below. A responder was defined by a score of 1 (very much improved), or 2 (much improved). 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse

    Time frame: Months 1, 3, 6, 9, 12

07

Results

Posted Jul 7, 2017

Participant flow

One hundred fifty-eight (158) of the 174 patients who completed 12 weeks of treatment in Study F202 were eligible and consented to participate in the 12-month safety extension study.

Participant flow — Overall Study
MilestonePlacebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8mg - TNX-102 SL 2.8 mg
Started7979
Completed4354
Not completed3625

Outcome measures

PrimaryNewly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL Tablets Taken Daily at Bedtime Over 12 Months in Patients With Fibromyalgia.

NEAEs and Serious Adverse events (SAEs) were collected and are coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA).

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Newly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL Tablets Taken Daily at Bedtime Over 12 Months in Patients With Fibromyalgia.
ParticipantsPlacebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg
Patient with at least 1 NEAE reported6054
Patients withdrew due to NEAE189
Patient with at least 1 SAE35
SecondaryChange From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on 24 Hour Recall

The NRS for average pain was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 24-hour recall basis.

Time frame:
Months 1, 3, 6, 9 and 12.
Reported as:
Mean · Scores on a scale
Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on 24 Hour Recall
Scores on a scalePlacebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg
Baseline5.6 ± 2.295.0 ± 2.52
Change at Month 1-0.5 ± 1.96-0.2 ± 1.75
Change at Month 3-0.5 ± 1.86-0.3 ± 1.92
Change at Month 6-0.7 ± 2.18-0.2 ± 2.32
Change at Month 9-0.6 ± 2.360.0 ± 1.91
Change at Month 120.1 ± 2.08-0.0 ± 2.26
SecondaryChange From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on a 7 Day Recall

The NRS for average pain over the past 7 days was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 7-day recall basis.

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · Scores on a scale
Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on a 7 Day Recall
Scores on a scalePlacebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg
Baseline5.7 ± 2.094.8 ± 2.18
Change at Month 1-0.8 ± 1.680.1 ± 1.13
Change at Month 3-0.6 ± 1.670.1 ± 1.85
Change at Month 6-0.7 ± 2.060.2 ± 2.11
Change at Month 9-0.4 ± 2.330.0 ± 2.07
Change at Month 120.0 ± 1.720.2 ± 1.84
SecondaryResponder Analysis of Patient's Global Impression of Change (PGIC)

PGIC is a fibromyalgia-specific validated instrument to gauge the patient's assessment of change in condition.The scores are categorized as provided below. A responder was defined by a score of 1 (very much improved), or 2 (much improved). 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse

Time frame:
Months 1, 3, 6, 9, 12
Reported as:
Count of participants · Participants
Responder Analysis of Patient's Global Impression of Change (PGIC)
ParticipantsPlacebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8mg - TNX-102 SL 2.8 mg
Month 1 — Score 1 or 21625
Month 1 — Scores 3 to 76354
Month 3 — Score 1 or 22329
Month 3 — Scores 3 to 75650
Month 6 — Score 1 or 22226
Month 6 — Scores 3 to 75753
Month 9 — Score 1 or 22127
Month 9 — Scores 3 to 75852
Month 12 — Score 1 or 21732
Month 12 — Scores 3 to 76247

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - TNX-102 SL 2.8 mg0/79 (0%)3/79 (3.8%)43/79 (54.4%)
TNX-102 SL 2.8mg - TNX-102 SL 2.8 mg0/79 (0%)5/79 (6.3%)39/79 (49.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8mg - TNX-102 SL 2.8 mg
AnxietyPsychiatric disorders0/791/79
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/791/79
Abdominal herniaGastrointestinal disorders0/791/79
Ankle fractureInjury, poisoning and procedural complications0/791/79
Brain stem gliomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/791/79
Pubic fractureInjury, poisoning and procedural complications1/790/79
VertigoEar and labyrinth disorders1/790/79
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/790/79
Most frequent other events
Most frequent other events
EventPlacebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8mg - TNX-102 SL 2.8 mg
Hypoaesthesia oralGastrointestinal disorders22/791/79
SinusitisInfections and infestations1/7910/79
Product taste abnormalGeneral disorders9/790/79
FatigueGeneral disorders3/798/79
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders0/796/79
GlossodyniaGastrointestinal disorders5/792/79
ConstipationGastrointestinal disorders2/794/79
SomnolenceNervous system disorders1/794/79
ParaesthesiaNervous system disorders0/794/79

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8 mg - TNX-102 SL 2.8 mgTotal
<=18 years000
Between 18 and 65 years7579154
>=65 years404
Age, Continuous
Age, Continuous(Years)Placebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8 mg - TNX-102 SL 2.8 mgTotal
Mean50.2 (19 to 65)51.7 (20 to 64)50.9 (19 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - TNX-102 SL 2.8 mgTNX-102 SL 2.8 mg - TNX-102 SL 2.8 mgTotal
Female7875153
Male145
08

Study locations

13 sites
  • Denver
    Denver, Colorado 80239, United States
  • 16176 Cortez Boulevard
    Brooksville, Florida 34601, United States
  • 100 West Gore Street
    Orlando, Florida 32806, United States
  • 71 Thomas Johnson Drive
    Frederick, Maryland 21702, United States
  • 370 Faunce Corner Road
    North Dartmouth, Massachusetts 02747, United States
  • Worcester
    Worcester, Massachusetts 01605, United States
  • Jackson
    Jackson, Mississippi 39202, United States
  • Cincinnati
    Cincinnati, Ohio 45219, United States
  • 1275 Olentangy River Road
    Columbus, Ohio 43212, United States
  • 18660 Bagley Road
    Middleburg Heights, Ohio 44130, United States
  • 1001 South Market Street
    Mechanicsburg, Pennsylvania 17055, United States
  • 322 Memorial Drive
    Greer, South Carolina 29650, United States
  • 601 Broadway
    Seattle, Washington 98122, United States
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2013
First posted
Dec 19, 2013
Start
Dec 2013
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Jul 7, 2017
Last update
Jul 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02015234
Responsible party
Sponsor
First posted
Dec 19, 2013
Start date
Dec 2013
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Jul 7, 2017
Last update
Jul 7, 2017

Study contacts

Gregory Sullivan
study director · Tonix Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion